Adverse events from nitrate administration during right ventricular myocardial infarction: a systematic review and meta-analysis
- 30 September 2022
- journal article
- review article
- Published by BMJ in Emergency Medicine Journal
- Vol. 40 (2) , 108-113
Abstract
Background: The current guidelines of the American Heart Association (AHA) and European Society of Cardiology (ESC) recommend that when right ventricular myocardial infarction (RVMI) is present patients are not administered nitrates, due to the risk that decreasing preload in the setting of already compromised right ventricular ejection fraction may reduce cardiac output and precipitate hypotension. The cohort study (n=40) underlying this recommendation was recently challenged by new studies suitable for meta-analysis (cumulatively, n=1050), suggesting that this topic merits systematic review. Methods: The protocol was registered on PROSPERO and published in Evidence Synthesis. Six databases were systematically searched in May 2022: PubMed, Embase, MEDLINE Complete, Cochrane CENTRAL Register, CINAHL and Google Scholar. Two investigators independently assessed for quality and bias and extracted data using Joanna Briggs Institute tools and methods. Risk ratios and 95% CIs were calculated, and meta-analysis performed using the random effects inverse variance method. Results: Five studies (n=1113) were suitable. Outcomes included haemodynamics, GCS, syncope, arrest and death. Arrest and death did not occur in the RVMI group. Meta-analysis was possible for sublingual nitroglycerin 400 μg (2 studies, n=1050) and found no statistically significant difference in relative risk to combined inferior and RVMI at 1.31 (95% CI 0.81 to 2.12, p=0.27), with an absolute effect of 3 additional adverse events per 100 treatments. Results remained robust under sensitivity analysis. Conclusions: This review suggests that the AHA and ESC contraindications are not supported by evidence. Key limitations include all studies having concomitant inferior and RVMI, not evaluating beneficial effects and very low certainty of evidence. As adverse events are transient and easily managed, nitrates are a reasonable treatment modality to consider during RVMI on current evidence. PROSPERO registration number: CRD42020172839.Keywords
Funding Information
- Australian Catholic University (MWS-2021)
This publication has 28 references indexed in Scilit:
- A basic introduction to fixed-effect and random-effects models for meta-analysisResearch Synthesis Methods, 2010
- Double JeopardyNew England Journal of Medicine, 2005
- Hemodynamic effects of inhaled nitric oxide in right ventricular myocardial infarction and cardiogenic shockJACC, 2004
- Significance of nitroglycerin-induced hypotension with inferior wall acute myocardial infarctionThe American Journal of Cardiology, 1989
- Comparative effects of volume loading, dobutamine, and nitroprusside in patients with predominant right ventricular infarction.Circulation, 1985
- A randomized prospective trial of intravenous nitroglycerin in patients with acute myocardial infarction.Circulation, 1983
- Segmental right ventricular function after acute myocardial infarction: Two-dimensional echocardiographic study in 63 patientsThe American Journal of Cardiology, 1983
- Hemodynamic spectrum of “dominant” right ventricular infarction in 19 patientsThe American Journal of Cardiology, 1981
- Reduction of CK and CK-MB indexes of infarct size by intravenous nitroglycerin.Circulation, 1981
- The noninvasive diagnosis of right ventricular infarction.Circulation, 1978